Begin main content

Panels

Clinical Guidance Panels

The pan-Canadian Oncology Drug Review (pCODR) relies on the medical expertise of its Clinical Guidance Panels to ensure that the review of each cancer drug draws from the most important, relevant, and current clinical information. There are 13 Clinical Guidance Panels, each offering expertise in a specific tumour site:

  • Breast Cancer
  • Endocrine Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecological Cancer
  • Head and Neck Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Myeloma
  • Neurological Cancer
  • Sarcoma
  • Skin and Melanoma

In cases where a drug is used to treat a tumour not addressed by any of the 13 Clinical Guidance Panels, pCODR will form an additional expert panel for the duration of the review.

For each pCODR review, the relevant Panel generates a Clinical Guidance document that is submitted to pCODR's Expert Review Committee (pERC). The document is used as part of pERC's deliberative process to make funding recommendations.

The panel may also provide input on a variety of issues, including current clinical practices, new approaches or literature related to tumour management, targeted molecular testing, and other clinical factors that may affect the drug's application for treating a specific tumour type. 

Membership

Each of the 11 Clinical Guidance Panels consists of three to five cancer specialists, recognized as experts for that specific tumour site, who apply for membership to the panel. Panel members must have experience in developing clinical guidelines for cancer treatment.

The final selection of panel members is made jointly by the Director,  pCODR and the Chair of pERC.

Leadership

Each Clinical Guidance Panel has a Lead who is appointed by the Director,  pCODR. The Panel Lead is generally the lead author for the guidance document submitted to pERC and serves as the main contact for further information.

Economic Guidance Panel

pCODR relies on the expertise of its Economic Guidance Panels to assess the economic evidence provided when a drug is submitted to pCODR.

For each pCODR review, a Panel generates an Economic Guidance report that is submitted to pERC. The document is used as part of pERC's deliberative process to make funding recommendations.

Input by the Economic Guidance Panels may include: qualitative and quantitative assessments of the submitted economic evidence; suggestions for improving the economic evidence submitted; and suggestions for national collaboration to improve the quality of economic evidence that can be used to further support decision-making.

Membership

The composition of each Economic Guidance Panel is tailored to the requirements of the drug submission under consideration. For each review, pCODR selects from a roster of panel members with expertise in health economics or clinical epidemiology. All panel members must have experience in applied health technology assessment.

Panel members are selected by the Director,  pCODR and the Chair of pERC.

Leadership

Each Economic Guidance Panel has a Lead who is appointed by the Director,  pCODR. The Panel Lead is generally the lead author for the guidance document submitted to pERC and serves as the main contact for further information.

Members of all Guidance Panels (Clinical/Economic)

Members of all panels must comply with the following:

Of note, all pCODR participants are required to follow the pCODR Code of Conduct, which specifies that participants:

  • shall be independent and impartial
  • shall not be influenced by self-interest, outside pressure, political considerations, or fear of criticism
  • shall not allow past or existing financial, business, professional, family, or social relationships or responsibilities to influence their conduct or judgment.

Please help us in supporting panel members to meet their obligations under the Code of Conduct by refraining from direct contact with them in their capacity as pCODR participants. All questions and/or correspondence regarding the pCODR process should be directed to Alexandra Chambers, Director,  pCODR at alexandrac@cadth.ca.

The following individuals are involved with pCODR Guidance Panels, or were involved with a review within the past two years.

Abha Gupta COI Margot Burnell | COI
Adam Raymakers | COI Matthew (Matt) Cheung | COI
Andrew G. Scarfe | COI Michael Crump | COI
Andrew Daly | COI Michael Smylie | COI
Anna Tinker | COI Murray Krahn | COI
Anthony Reiman | COI Nadia Coakley | COI
Carlo Marra | COI Natasha Leighl | COI
Catherine Moltzan | COI Parneet Cheema | COI
Christian Kollmannsberger | COI Patricia Tang | COI
Christine Brezden-Masley | COI Petros Pechlivanoglou | COI
Christopher Lee | COI Prafull Ghatage | COI
Cindy Quinton | COI Ronald (Ron) Burkes | COI
Craig Earle | COI Sara Kuruvilla | COI
Dan Cooper | COI Scott Ernst | COI
Daniel Rayson | COI Scott Laurie | COI
Dean Ruether | COI Sharlene Gill | COI
Dominika Wranik | COI Shawn Bugden | COI
Don Husereau | COI Simron Singh  | COI
Don Morris | COI Siu-Chung (Quincy) Chu | COI
Doug Coyle | COI Sonal Gandhi | COI
Eric Winquist | COI Srikala Sridhar | COI
Eva Tsakonas | COI Stella Chen | COI
Gary Pansegrau | COI Stephen Chia | COI
Georg Bjarnason | COI Sukhbinder (Bindi) Dhesy-Thind | COI
Greg Zaric | COI Susan Dent | COI
Jaclyn Beca | COI Tania Conte | COI
Jason Hart | COI Tien Le | COI
Jeff Lipton | COI Tricia Waldron | COI
Kelvin Chan | COI Vera Hirsh | COI
Laurel Kovacic | COI Vishal Kukreti | COI
Laurie Elit | COI Vivien Bramwell | COI
Lianne Barnieh | COI Wan Ki (Gavin) Wong | COI
Lisa Hicks | COI Yasmin Rahim | COI
Louise Bordeleau | COI Yoo-Joung (Yooj) Ko | COI
Marc Kerba | COI